Sangamo Biosciences Has Option to Acquire Gendaq in Stock Deal Worth $40M

May 30, 2001

NEW YORK, May 30 - Sangamo Biosciences said Wednesday it has obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million.

Sangamo, which is currently completing due diligence, has until July 14 to exercise its option to acquire Gendaq, a London-based developer of zinc finger DNA binding proteins for gene regulating gene expression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in PNAS

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

Choice Against Testing

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

Call for Gene Editing Oversight

The Japan Times says regulations are needed to oversee human genome-editing research.

This Week in PLOS

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Main menu